Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Barliz Waissengrin"'
Autor:
Moran Gvili Perelman, Rafael Y. Brzezinski, Barliz Waissengrin, Yasmin Leshem, Or Bainhoren, Tammi Arbel Rubinstein, Maxim Perelman, Zach Rozenbaum, Ofer Havakuk, Yan Topilsky, Shmuel Banai, Ido Wolf, Michal Laufer-Perl
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are
Externí odkaz:
https://doaj.org/article/92fb64f1df084550a222a0e7d6ae6d4c
Autor:
Barliz Waissengrin, Dan Mirelman, Sharon Pelles, Felix Bukstein, Deborah T. Blumenthal, Ido Wolf, Ravit Geva
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dosage-limited oxaliplatin-related toxicity. To date, there are no successful interventions for CIPN prevention or treatment. A therapeutic role for cannabis in diabetic an
Externí odkaz:
https://doaj.org/article/d8365397257944cc9beb3795921e4cc6
Publikováno v:
Breast Care (Basel)
Background: Most patients with HER2-positive metastatic breast cancer (MBC) receive first-line treatment with anti-HER2 agents and have already received anti-HER2 therapy as adjuvant or neoadjuvant therapy in the local setting of their disease presen
Autor:
Barliz Waissengrin, Yasmin Leshem, Marwa Taya, David Meiri, Ofer Merimsky, Sivan Shamai, Ido Wolf, Tami Rubinek
Publikováno v:
European journal of cancer (Oxford, England : 1990). 180
The use of medical cannabis has rapidly increased among cancer patients worldwide. Cannabis is often administered concomitantly with cancer medications, including immune checkpoint inhibitors (ICIs). As the cannabinoid receptors are abundantly expres
Autor:
Barliz Waissengrin, Ellie Leidner, Nadav Mishaan, Tamar Safra, Diana Matceyevsky, Ido Laskov, Ido Wolf, Rotem Merose, Talya Levy, Rotem Shayzaf, Dan Grisaru
Publikováno v:
The Oncologist. 26:30-39
Background Conventional first-line combination therapy for ovarian cancer comprises 6 cycles of adjuvant or neoadjuvant carboplatin (AUC5-6) with paclitaxel (175 mg/m2) every 3 weeks (PC-3W). Weekly scheduling of paclitaxel may maximize its antiangio
Publikováno v:
The Israel Medical Association journal : IMAJ. 23(7)
Publikováno v:
Journal of Clinical Oncology. 40:e21097-e21097
e21097 Background: In recent years, the use of medical cannabis rapidly increased among cancer patients in Israel. Yet, cannabinoid receptors are abundantly expressed on immune cells and modulate their activity. It is abundantly being use by metastat
Publikováno v:
The Lancet. Oncology
Autor:
Franco M. Muggia, Dana Josephy, Melissa K. Frey, Lina Salman, T. Safra, Rinat Bernstein-Molho, Rakefet Chen-Shtoyerman, Ilan Bruchim, Deanna Gerber, Geula Klorin, Bhavana Pothuri, Barliz Waissengrin
Publikováno v:
Gynecologic oncology. 162(3)
Objectives We evaluated the incidence of breast cancer and overall survival in a multi-center cohort of ovarian cancer patients carrying BRCA1/2 mutations in order to assess risks and formulate optimal preventive interventions and/or surveillance. Me
Autor:
Tamar Safra, Sharon Pelles, Shira Peleg Hasson, Ravit Geva, Eliya Shachar, Ido Wolf, Mirika Brezis, Marah Hodruj, Rochelle Fayngor, Alla Nikolaevski-Berlin, Barliz Waissengrin
Publikováno v:
The Oncologist
Introduction The use of telemedicine in oncology practice is rapidly expanding and is considered safe and cost effective. However, the implications of telemedicine on patient‐physician interaction, patient satisfaction, and absence of the personal